Characterizing Fatigue by Multiple Sclerosis Subtype and Determining Validity of a Fatigue Scale Specific to Persons With Progressive Multiple Sclerosis
- PMID: 39403368
- PMCID: PMC11471975
- DOI: 10.7224/1537-2073.2023-107
Characterizing Fatigue by Multiple Sclerosis Subtype and Determining Validity of a Fatigue Scale Specific to Persons With Progressive Multiple Sclerosis
Abstract
Background: Fatigue is a common and debilitating symptom of multiple sclerosis (MS). Prior work suggests that the prevalence of fatigue is higher in progressive MS (PMS) than relapsing MS (RRMS). No patient-reported outcomes of fatigue have been validated specifically for individuals with PMS, despite evidence that they characterize fatigue differently than individuals with RRMS. Therefore, the objective of this study was to characterize fatigue in both the RRMS and PMS subtypes and determine the convergent validity of the Fatigue Symptoms and Impacts Questionnaire (FSIQ) for individuals with PMS.
Methods: A nationwide survey yielded 806 (637 RRMS, 169 PMS) complete responses. The survey collected demographic information and self-reported disease severity, as well as measures of fatigue, health-related quality of life, and self-reported functioning.
Results: People with PMS reported significantly more severe fatigue than those with RRMS (P < .001). The FSIQ subdomains of physical, cognitive/emotional, and coping demonstrated moderate (r = 0.5-0.75) to excellent (r > 0.75) validity (P < .001) with other measures of fatigue.
Conclusions: More severe fatigue in people with PMS as compared to those with RRMS underscores the importance of using validated tools to capture fatigue in persons with PMS. The FSIQ is a valid and freely available tool to capture the physical, mental, and emotional fatigue of individuals with PMS.
Keywords: fatigue; fatigue scale; progressive multiple sclerosis.
© 2024 Consortium of Multiple Sclerosis Centers.
Similar articles
-
A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis.Mult Scler Relat Disord. 2022 Jul;63:103918. doi: 10.1016/j.msard.2022.103918. Epub 2022 May 28. Mult Scler Relat Disord. 2022. PMID: 35700673
-
Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis.Mult Scler Relat Disord. 2021 Sep;54:103109. doi: 10.1016/j.msard.2021.103109. Epub 2021 Jun 23. Mult Scler Relat Disord. 2021. PMID: 34237561
-
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis.Value Health. 2019 Apr;22(4):453-466. doi: 10.1016/j.jval.2018.11.007. Epub 2019 Feb 21. Value Health. 2019. PMID: 30975397
-
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.Curr Med Res Opin. 2021 Jun;37(6):995-1004. doi: 10.1080/03007995.2021.1904860. Epub 2021 Apr 6. Curr Med Res Opin. 2021. PMID: 33733976
-
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.Neurotherapeutics. 2022 Apr;19(3):774-784. doi: 10.1007/s13311-022-01214-x. Epub 2022 Mar 14. Neurotherapeutics. 2022. PMID: 35289375 Free PMC article. Review.
References
-
- Hudgens S, Schüler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health. 2019;22:453–466. doi: 10.1016/j.jval.2018.11.007. doi: - DOI - PubMed
LinkOut - more resources
Full Text Sources